



ASX Announcement

Date of AGM and Closing Date for Director Nominations

Sydney, 9 October 2020 - Race Oncology Limited ASX: RAC (RAC or the Company) advises, in accordance with ASX Listing Rule 3.13.1, that its Annual General Meeting will be held on Monday, 30 November 2020. The Company will follow the measures in place as set by the Australian and New South Wales governments for the restriction of gatherings and the implementation of social distancing requirements in response to COVID-19.

An item of business at the AGM will be the re-election and appointment of directors. In accordance with clause 14.3 of the Company's Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a director is Monday, 19 October 2020.

Any nominations must be received at the Company's registered office no later than 5:00 pm (Sydney time) on Monday, 19 October 2020.

-ENDS-

About Race Oncology (RAC: ASX)

Race Oncology (RAC) is a drug development biotech with a Phase II/III cancer drug called Bisantrone. RAC has compelling clinical data for Bisantrone in acute myeloid leukaemia (AML) as well as breast and ovarian cancer. RAC is pursuing an exciting '5-Path' clinical development strategy that involves parallel Israeli, US and Australian clinical trials in AML, breast and ovarian beginning in 2020.

Release authorised by:

Mr Phillip Lynch, Managing Director

+61 427 222 707

phillip.lynch@raceoncology.com

Media contact:

Jane Lowe, IR Department

+ 61 411 117 774

jane.lowe@irdepartment.com.au